SmartCella Holding AB Email Format
Biotechnology ResearchStockholm, Sweden51-200 Employees
SmartCella Holding AB is a biotechnology research company based in Tullinge, in the Stockholm region of Sweden. Founded in 2014, it builds on science from Karolinska Institutet to develop therapies derived from living systems and pursue targeted approaches for difficult-to-treat diseases through delivery solutions and advanced therapy development. The company has two operating segments, Targeted Delivery and Regenerative Medicines, and has developed the Extroducer, an endovascular delivery device that enables direct injection to hard-to-reach organs and tumors, alongside development and manufacturing of cell therapies. Its focus is on researchers and biopharma developers seeking novel delivery and cell-therapy platforms. In May 2026, SmartCella announced a licensing agreement with Oloker Therapeutics to extend Extroducer technology for targeted delivery.